Astrazeneca Ab

Medimmune Limited

Bing Wang

Lorin Roskos

Christine K Ward

Donald Raible

Brandon Higgs

Yihong Yao

Linda Chang

The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.

Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies

Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

Methods for improving asthma symptoms using benralizumab

Provided herein is are methods of increasing forced expiratory volume in one second (FEV) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

Methods for increasing forced expiratory volume in asthmatics using benralizumab

Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.

Growing community of inventors

Gaithersburg, MD, United States of America

Bing Wang